10x Genomics (TXG) Expected to Announce Earnings on Thursday

Key Points

• 10x Genomics is set to announce its Q2 2025 earnings results on August 7th, with analysts projecting an EPS of ($0.35) and revenue of $139.36 million for the quarter.
• In its last earnings report, 10x Genomics beat analysts' expectations, reporting an EPS of ($0.36) and revenue of $154.88 million, though its revenue decreased by 2.3% year-over-year.
• Insider trading activity included the sale of shares by CEO Serge Saxonov and other insiders in May, indicating some selling pressure on the stock.

10x Genomics (NASDAQ:TXG - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect 10x Genomics to post earnings of ($0.35) per share and revenue of $139.36 million for the quarter. 10x Genomics has set its Q2 2025 guidance at EPS.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative net margin of 25.14% and a negative return on equity of 23.22%. The company had revenue of $154.88 million during the quarter, compared to the consensus estimate of $131.91 million. During the same period last year, the firm earned ($0.50) EPS. The firm's revenue for the quarter was down 2.3% compared to the same quarter last year. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

Shares of TXG traded down $0.37 during mid-day trading on Friday, reaching $13.08. The company had a trading volume of 2,650,226 shares, compared to its average volume of 2,984,432. The company has a market capitalization of $1.61 billion, a P/E ratio of -10.06 and a beta of 2.03. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $24.76. The company's 50-day moving average is $11.51 and its 200-day moving average is $10.88.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Bank of America upped their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. Barclays reiterated an "overweight" rating and issued a $13.00 target price (up previously from $12.00) on shares of 10x Genomics in a research note on Tuesday, June 24th. Wall Street Zen lowered 10x Genomics from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. The Goldman Sachs Group decreased their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research report on Monday, May 12th. Finally, Morgan Stanley decreased their price target on 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, 10x Genomics has a consensus rating of "Hold" and an average target price of $13.23.

Insider Activity

In other news, CEO Serge Saxonov sold 9,343 shares of the firm's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $77,546.90. Following the transaction, the chief executive officer owned 1,083,625 shares of the company's stock, valued at approximately $8,994,087.50. This trade represents a 0.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 7,485 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $62,125.50. Following the completion of the sale, the insider owned 448,374 shares in the company, valued at $3,721,504.20. This represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,872 shares of company stock valued at $173,238. 9.39% of the stock is currently owned by insiders.

Institutional Trading of 10x Genomics

A number of hedge funds have recently modified their holdings of TXG. Focus Partners Wealth acquired a new stake in 10x Genomics during the 1st quarter worth approximately $92,000. Royal Bank of Canada raised its holdings in 10x Genomics by 806.4% during the 1st quarter. Royal Bank of Canada now owns 182,836 shares of the company's stock worth $1,597,000 after buying an additional 162,665 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in 10x Genomics by 163.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company's stock worth $5,634,000 after buying an additional 400,430 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.